CHGCF - Chugai Biofourmis expand team up on digital solutions to measure endometriosis pain

Chugai Pharmaceutical ( OTCPK:CHGCF ) ( OTCPK:CHGCY ) and Biofourmis signed a new collaboration agreement for the continued development and real-world use of digital solutions to measure pain in patients with endometriosis.

Endometriosis is a condition in which cells similar to endometrium (the lining of the uterus) grow outside the uterus. According to the companies, Endometriosis affects about 10% of all women of reproductive age and 70% of women with chronic pelvic pain.

Since July 2020, the two companies have been collaborating to develop a new objective assessment of pain in patients with endometriosis using a biosensor and an AI-based algorithm using Biofourmis' Biovitals platform.

As pain is a subjective symptom, it can be difficult to accurately convey the degree of pain patients experience, the companies noted.

The companies added that the digital solutions will be rolled out for real-world use with support from Biofourmis' virtual specialty care services in the U.S., using Chugai's R&D data.

The partnership will focus on continuing developing objective measurement technology for pain linked with endometriosis; advancing a technology platform for a real-world data driven pain measurement; Virtual specialty care by Biofourmis for these patients in the U.S.

The companies will also focus on using data collected during research and development and post-marketing of Chugai's investigational product AMY109 to treat endometriosis pain.

"Expanding this collaboration from research and development to real-world use demonstrates the scalability and flexibility of Biofourmis' end-to-end platform and solutions for both drug development and healthcare delivery," said Biofourmis Founder and CEO Kuldeep Rajput.

Tokyo-based Chugai is a member of the Roche Group ( OTCQX:RHHBY ) ( OTCQX:RHHBF ).

For further details see: